CIK 0001653087 · Accelerated filer<br>Smaller reporting company
Alector, Inc.
Sign in to watch- Ticker
- ALEC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 822933343
- Phone
- 415-231-5660
- Business address
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Alector LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $296,087
- in 3 filings
Net −$296,087. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 76 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-29 | Polaris Venture Management Co. VI, L.L.C. 10% owner | Other disposition | −500,000 | 9,853,817 | ||
| 2024-05-29 | Polaris Venture Management Co. VI, L.L.C. 10% owner | Other acquisition | +98,533 | 98,533 | ||
| 2024-05-29 | Polaris Venture Management Co. VI, L.L.C. 10% owner | Other disposition | −98,533 | 0 | ||
| 2024-04-30 | Polaris Venture Management Co. VI, L.L.C. 10% owner | Other disposition | −500,000 | 10,353,817 | ||
| 2024-04-30 | Polaris Venture Management Co. VI, L.L.C. 10% owner | Other acquisition | +98,533 | 98,533 | ||
| 2024-04-30 | Polaris Venture Management Co. VI, L.L.C. 10% owner | Other disposition | −98,533 | 0 | ||
| 2024-03-19 | Altmeyer Mark Director | Grant or award | +41,250 | 41,250 | ||
| 2024-03-19 | Altmeyer Mark Director | Grant or award · Stock Option (right to buy) | +19,420 | 19,420 | ||
| 2024-03-19 | DESOUZA ERROL B Director | Grant or award | +41,250 | 41,250 | ||
| 2024-03-19 | DESOUZA ERROL B Director | Grant or award · Stock Option (right to buy) | +19,420 | 19,420 | ||
| 2024-03-04 | Romano Gary Chief Medical Officer | Sale | −6,001 | $6.92 | $42K | 196,313 |
| 2024-03-04 | Kenkare-Mitra Sara President and Head of R&D | Sale | −10,169 | $6.92 | $70K | 318,847 |
| 2024-03-04 | GRASSO MARC Chief Financial Officer | Sale | −5,716 | $6.92 | $40K | 144,957 |
| 2024-03-04 | Rosenthal Arnon Chief Executive Officer | Sale | −18,837 | $6.92 | $130K | 2,000,380 |
| 2023-12-05 | GAROFALO ELIZABETH A. Director | Gift | −9,459 | 26,250 | ||
| 2023-12-04 | Rosenthal Arnon Chief Executive Officer | Sale | −23,831 | $5.56 | $133K | 2,019,217 |
| 2023-12-04 | Romano Gary Chief Medical Officer | Sale | −5,035 | $5.56 | $28K | 202,314 |
| 2023-12-04 | GRASSO MARC Chief Financial Officer | Sale | −4,574 | $5.56 | $25K | 150,673 |
| 2023-12-04 | Kenkare-Mitra Sara President and Head of R&D | Sale | −12,519 | $5.56 | $70K | 329,016 |
| 2023-10-01 | Romano Gary Chief Medical Officer | Grant or award | +108,000 | 207,349 |
Page 8 of 23 · 454 trades